Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

/

CING

C

Cingulate Inc. (CING)

NCM – Real vaqt narxi. Valyuta: USD

4.79

-0.17 (-3.43%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.95

+0.16 (3.34%)

Bozor oldidan: May 13, 2026, 4:56 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.

Why did Cingulate stock skyrocket today?

Why did Cingulate stock skyrocket today?

Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tablet.” This regulatory victory effectively safeguards the proprietary technology behind Cingulate's lead ADHD candidate – CTx-1301 – providing a massive boost to investor confidence as the company prepares for a transformative year.

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise.

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients

Videolar

No Data

There is no data to display

Press-relizlar

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25

Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance.

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflect continued progress toward transforming CTx-1301 into a commercial ADHD franchise.

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients